#United States #biopharmaceuticals #San Antonio #Entolimod #Valion Bio

Tivic Health Systems Rebrands as Valion Bio

In a significant corporate transformation, Tivic Health Systems, Inc. has announced its rebranding as Valion Bio, Inc., effective April 28, 2026. This strategic shift marks the completion of a fundamental change as the company pivots from consumer medical devices to establishing itself as a late-stage biopharmaceutical firm. With a new Nasdaq ticker symbol, VBIO, the company aims to reflect its renewed focus on groundbreaking biopharmaceuticals, underpinned by substantial government-backed assets.

Overview of the Transformation

The rebranding signifies much more than a mere name change; it encapsulates a complete overhaul of the company's operational model. Valion Bio will concentrate on developing a late-stage biopharmaceutical platform, delineating a clear departure from its previous venture. The move is directly tied to the development of its lead drug candidate, Entolimod™, which boasts over 15 years of extensive research and development, alongside substantial investment exceeding $140 million.

Entolimod is recognized as an innovative Toll-like receptor 5 (TLR5) agonist, making it an invaluable medical countermeasure against Acute Radiation Syndrome (ARS). The drug has already garnered FDA Fast Track and Orphan Drug designations, positioning Valion Bio favorably as it seeks inclusion in the U.S. Strategic National Stockpile through ongoing collaboration with governmental agencies like BARDA and DTRA.

Navigating Regulatory Landscapes

This drug is developed under the FDA’s Animal Rule, a regulation that permits the approval of drugs based on the results of animal studies when human trials cannot be ethically conducted. This regulatory approach is designed to minimize the inherent risks and challenges of new drug development. If Valion Bio secures a procurement contract from the government, it could result in a significant revenue influx without diluting shareholder interests.

Entolimod's pharmacological action focuses on cytoprotection of bone marrow and gastrointestinal epithelial tissues, revealing its potential for treating chemotherapy-induced neutropenia. The global market for neutropenia treatments is substantial, projected to reach nearly $30 billion by the early 2030s. In response, Valion Bio is aiming for physician-sponsored clinical trials in chemotherapy-induced neutropenia, with plans to enter Phase IIb trials this year.

Leadership and Management

Michael K. Handley, who has been pivotal in advancing Entolimod while at Statera Biopharma, has taken the helm as CEO of Valion Bio. His extensive knowledge of regulatory affairs and strategic partnerships underscores his capability to steer the company in this new direction. Under his leadership, there is a concentrated effort to unify scientific, commercial, and operational endeavors, a crucial aspect given the complexity of drug development and market introduction.

Velocity Bioworks: A Strategic Asset

As part of this strategic evolution, Valion Bio has integrated its subsidiary, Velocity Bioworks, which provides in-house manufacturing capabilities for Entolimod. Acquired for approximately $16.3 million, the subsidiary not only ensures secure supply chains critical for government contracts but also has the potential to generate revenue independently by serving third-party biotech clients. Recently, Velocity Bioworks successfully scaled up Entolimod production significantly, demonstrating operational efficiency and adherence to regulatory specifications.

Positioning for the Future

The choice of San Antonio, Texas, as the headquarters reflects Valion Bio's intent to be strategically situated near vital networks within the DoD's biodefense ecosystem. This location is instrumental considering the emphasis on domestic biomanufacturing and increasing awareness of national preparedness amidst evolving global threats.

As Valion Bio positions itself at the forefront of biopharmaceuticals, it aims to navigate a landscape marked by shifting regulatory environments, heightened focus on public health, and the demands of national stockpiling programs. The commitment to innovation and government collaboration will be crucial for navigating the complexities of the biopharmaceutical industry.

In summary, the rebranding to Valion Bio represents a bold step into a promising future, where the company's assets and expertise can enable it to thrive in the critical and expanding field of biopharmaceuticals. For further information on Valion Bio, visit Valion Bio Investor Relations.